Whippany-based Bayer announced on April 20 that two of its top pharmaceutical executives, Nelson Ambrogio and John Berrios, will take on new leadership roles within the division to advance its position in key therapeutic areas.
Ambrogio, formerly the senior vice president, general manager of Women’s Health Care was appointed to the role of senior vice president, general manager of Oncology. And Berrios, formerly vice president of Commercial Operations, will become the senior vice president, general manager of Women’s Health Care.
Both will serve on the U.S. Pharmaceutical Leadership Team and report directly to Sebastian Guth, Bayer’s president of Pharmaceuticals, Americas Region.
Ambrogio
“Nelson and John are passionate, well-respected leaders in the pharmaceutical industry and have a proven track record of launching products, developing rising leaders and driving growth,” said Guth. “The U.S. Pharmaceuticals Business is central to Bayer’s success. I’m confident that under their leadership, the Oncology and Women’s Healthcare franchises will continue on a growth path and further strengthen our overall business in the U.S.”
Prior to his current appointment as senior vice president and general manager of Oncology, Ambrogio oversaw the sales and marketing teams for the company’s contraceptive franchise. Before that, he held multiple leadership positions within Bayer worldwide.
Berrios
After five years at Bayer, Berrios will lead the Women’s Health Care business in the U.S. starting May 1. Since joining Bayer in 2016, he has held multiple leadership roles in market access and operations. In his previous role as vice president of Commercial Operations, he led enterprise-wide operations for the pharmaceutical division, as well as advanced the company’s digital transformation by building a best-in-class in-house media team.
Prior to joining Bayer, Berrios spent more than 15 years at AstraZeneca in various roles, including sales, market access and marketing positions. He served as the senior director of patient engagement, where he was responsible for leading the marketing and patient engagement programs across the company’s portfolio including cardiovascular, diabetes, respiratory, specialty and oncology divisions.
